Your session is about to expire
← Back to Search
PET/CT Scans for Neuroendocrine Cancer
Study Summary
This trial is testing three different ways to detect neuroendocrine tumors, to see which is most effective.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am under 40 years old.I am 40 years old or older.I weigh less than 225 kg.I have at least two lesions suspected to be a neuroendocrine tumor.I have a confirmed diagnosis of a neuroendocrine tumor.
- Group 1: 18F-DOPA PET/CT scan
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is the recruitment phase of this research still open?
"Right, the latest information from clinicaltrials.gov confirms that this experiment is currently searching for participants to join. It was first advertised on October 15th 2022 and was recently modified on November 16th 2022. This trial seeks 50 patients at a single facility."
What potential risks could arise from administering 18F-DOPA with furosemide to individuals?
"After carefully evaluating the Phase 2 trial data, our team at Power determined that 18F-DOPA with furosemide is safe and gave it a rating of 2."
How many volunteers are involved in this medical experiment?
"Affirmative. The clinical trial information displayed on clinicaltrials.gov confirms that this medical study, which was initially posted on October 15th 2022, is actively recruiting patients. Around 50 individuals need to be enlisted from a single centre."
Share this study with friends
Copy Link
Messenger